Going, going, gone? That could be the question that (NASDAQ: NVCR) investors are asking these days. Shares of the oncology company plunged 56% in 2021. The stock slid 2% lower last year. And so far in 2023, Novocure is down around 13%.

However, some would argue that the best days for the company lie ahead. Should you buy Novocure stock right now? Here are the cases both for and against this beaten-down cancer stock.

Let's start with the pessimistic view. When a stock falls as much as Novocure has over the last couple of years or so, there's always an underlying reason.

Continue reading

Source Fool.com